In a classic follow-up report, up to 50% of patients with acute lymphoblastic leukemia treated with anti-CD19-CAR-T cells relapsed within the first year, and a significant proportion of them exhibited CD19 antigen loss 126. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.